Pajjiż: Malasja
Lingwa: Ingliż
Sors: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
V.CHOLERAE INABA 48 CLASSICAL BIOTYPE,; V.CHOLERAE INABA 6973 EL TOR BIOTYPE,; V.CHOLERAE OGAWA 50 CLASSICAL BIOTYPE,; V.CHOLERAE OGAWA 50 CLASSICAL BIOTYPE,; Vibrio Cholerae 0139, Strain 4260 B, Inactivated
AVERROES PHARMACEUTICALS SDN. BHD.
V.CHOLERAE INABA 48 CLASSICAL BIOTYPE,; V.CHOLERAE INABA 6973 EL TOR BIOTYPE,; V.CHOLERAE OGAWA 50 CLASSICAL BIOTYPE,; V.CHOLERAE OGAWA 50 CLASSICAL BIOTYPE,; Vibrio Cholerae 0139, Strain 4260 B, Inactivated
50 Units; 5 Units; 10 Units
Eubiologics Co., Ltd
Not applicable Aqra d-dokument sħiħ
Euvichol-Plus Suspension Oral Cholera Vaccine Vibrio cholerae O1 Inaba Cairo 48 (H eat inactivated) Vibrio cholerae O1 Inaba Phil 6973 El Tor(Formalin inactivated) Vibrio cholerae O1 Ogawa Cairo 50 (Formalin inactivated) Vibrio cholerae O1 Ogawa Cairo 50 (Heat inactivated) Vibrio cholerae O139 4260B (Formalin inactivated) P roduct Name Euvichol-Plus Suspension Oral Cholera Vaccine P roduct Description A plastic tube filled with a yellow to yellowish suspension consists of inactivated V. cholerae Composit ion One dose (1.5 mL) contains: Active ingredients: V. cholerae O 1 Inaba Cairo 48 classical biotype, Heat inactivated…………..300 L.E.U V. cholerae O 1 Inaba Phil 6973 El Tor biotype , Formalin inactivated …… …600 L.E.U V. cholerae O1 O gawa Cairo 50 classical biotype, Formali n inactivated……300 L.E.U V. cholerae O1 O gawa Cairo 50 cl assical biotype, Heat inactivated………...300 L.E.U V. cholerae O139 4260B, Formalin inactivated …………………………\ …..600 L.E.U I ndication Euvichol- plus is indicated for active immuniz ation against Vibrio cholerae but the efficacy against Vibrio cholerae serogroup O139 was not demonstrated. The vaccine can be administered to anyone above the age of 1 year. Data for the safety and efficacy of the vaccine in infants (less than 1 year of age) is not available. The earliest onset of protection can be expected 7 -10 days after the completion of the primary series of the vaccine. R ecommended Dosage Two doses of vaccines should be given at an interval of two weeks. R oute of Administration Th e vaccine is only recommended for oral administration. C ontraindications - The vaccine should not be administered to persons with either known hypersensitivity to any component of the vaccine, or having shown signs of severe reaction due to the previously t aken dose. Aqra d-dokument sħiħ